Results 91 to 100 of about 20,376 (259)

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea   +5 more
wiley   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan   +7 more
wiley   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert   +12 more
wiley   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii   +5 more
wiley   +1 more source

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2016
Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK   +7 more
doaj  

Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2022
Ahmed Fouad Algendy,1 Ben Illigens,2 Ameena Alyazeedi3 1Clinical Pharmacy, Geriatric Department, Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar; 2Dresden International University, Division of Health Care Sciences, Center for Clinical Research ...
Fouad Algendy A, Illigens B, Alyazeedi A
doaj  

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg   +10 more
wiley   +1 more source

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard   +7 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang   +7 more
wiley   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy